With an oversubscribed March placing and the appointment of a new Chairman, pharmaceutical development company Nuformix PLC (LON:NFX) is galvanised to deliver its pipeline of assets.
The business targets unmet medical needs in fibrosis and oncology via drug repurposing, and Chief executive Dr Anne Brindley tells Proactive London that the refreshed board "is committed to optimising value from its existing assets while maintaining tight control of costs."
Brindley says there are three ways the company aims to achieve this goal. By doing further preclinical work on the lead asset NXP002, by pursuing licensing of NXP001 and by conducting further research and possibly a patent application filing on NXP004.